631 related articles for article (PubMed ID: 32470562)
41. Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation.
Luo M; Liu Q; Xiao L; Xiong LS
J Health Popul Nutr; 2022 May; 41(1):21. PubMed ID: 35578355
[TBL] [Abstract][Full Text] [Related]
42. Distinctions Between Fecal and Intestinal Mucosal Microbiota in Subgroups of Irritable Bowel Syndrome.
Hou Y; Dong L; Lu X; Shi H; Xu B; Zhong W; Ma L; Wang S; Yang C; He X; Zhao Y; Wang S
Dig Dis Sci; 2022 Dec; 67(12):5580-5592. PubMed ID: 35879512
[TBL] [Abstract][Full Text] [Related]
43. Fecal Microbiota of Diarrhea-Predominant Irritable Bowel Syndrome Patients Causes Hepatic Inflammation of Germ-Free Rats and Berberine Reverses It Partially.
Jia Q; Zhang L; Zhang J; Pei F; Zhu S; Sun Q; Duan L
Biomed Res Int; 2019; 2019():4530203. PubMed ID: 31073525
[TBL] [Abstract][Full Text] [Related]
44. Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies.
Wang L; Alammar N; Singh R; Nanavati J; Song Y; Chaudhary R; Mullin GE
J Acad Nutr Diet; 2020 Apr; 120(4):565-586. PubMed ID: 31473156
[TBL] [Abstract][Full Text] [Related]
45. Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome.
Sundin J; Aziz I; Nordlander S; Polster A; Hu YOO; Hugerth LW; Pennhag AAL; Engstrand L; Törnblom H; Simrén M; Öhman L
Sci Rep; 2020 Jan; 10(1):593. PubMed ID: 31953505
[TBL] [Abstract][Full Text] [Related]
46. Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome.
Mizuno S; Masaoka T; Naganuma M; Kishimoto T; Kitazawa M; Kurokawa S; Nakashima M; Takeshita K; Suda W; Mimura M; Hattori M; Kanai T
Digestion; 2017; 96(1):29-38. PubMed ID: 28628918
[TBL] [Abstract][Full Text] [Related]
47. The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel Syndrome.
Iribarren C; Magnusson MK; Vigsnæs LK; Aziz I; Amundsen ID; Šuligoj T; Juge N; Patel P; Sapnara M; Johnsen L; Sørensen N; Sundin J; Törnblom H; Simrén M; Öhman L
Nutrients; 2021 Oct; 13(11):. PubMed ID: 34836092
[TBL] [Abstract][Full Text] [Related]
48. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.
Peralta S; Cottone C; Doveri T; Almasio PL; Craxi A
World J Gastroenterol; 2009 Jun; 15(21):2628-31. PubMed ID: 19496193
[TBL] [Abstract][Full Text] [Related]
49. [Comparison of gut microbiotal compositional analysis of patients with irritable bowel syndrome through different bioinformatics pipelines].
Zhu SW; Liu ZJ; Li M; Zhu HQ; Duan LP
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Apr; 50(2):231-238. PubMed ID: 29643520
[TBL] [Abstract][Full Text] [Related]
50. Increased
Ponziani FR; Scaldaferri F; De Siena M; Mangiola F; Matteo MV; Pecere S; Petito V; Sterbini FP; Lopetuso LR; Masucci L; Cammarota G; Sanguinetti M; Gasbarrini A
Benef Microbes; 2020 Oct; 11(6):519-525. PubMed ID: 32885687
[TBL] [Abstract][Full Text] [Related]
51. Effect of water extract from Berberis heteropoda Schrenk roots on diarrhea-predominant irritable bowel syndrome by adjusting intestinal flora.
Zhu HM; Li L; Li SY; Yan Q; Li F
J Ethnopharmacol; 2019 Jun; 237():182-191. PubMed ID: 30902748
[TBL] [Abstract][Full Text] [Related]
52. Similar Fecal Microbiota Signatures in Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression.
Liu Y; Zhang L; Wang X; Wang Z; Zhang J; Jiang R; Wang X; Wang K; Liu Z; Xia Z; Xu Z; Nie Y; Lv X; Wu X; Zhu H; Duan L
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1602-1611.e5. PubMed ID: 27266978
[TBL] [Abstract][Full Text] [Related]
53. Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.
Rezaie A; Heimanson Z; McCallum R; Pimentel M
Am J Gastroenterol; 2019 Dec; 114(12):1886-1893. PubMed ID: 31688023
[TBL] [Abstract][Full Text] [Related]
54. Interplay between bile acid metabolism and microbiota in irritable bowel syndrome.
Dior M; Delagrèverie H; Duboc H; Jouet P; Coffin B; Brot L; Humbert L; Trugnan G; Seksik P; Sokol H; Rainteau D; Sabate JM
Neurogastroenterol Motil; 2016 Sep; 28(9):1330-40. PubMed ID: 27060367
[TBL] [Abstract][Full Text] [Related]
55. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
[TBL] [Abstract][Full Text] [Related]
56. A meta-analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome.
Ghoshal UC; Nehra A; Mathur A; Rai S
J Gastroenterol Hepatol; 2020 Jun; 35(6):922-931. PubMed ID: 31750966
[TBL] [Abstract][Full Text] [Related]
57. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota.
Jin Y; Ren X; Li G; Li Y; Zhang L; Wang H; Qian W; Hou X
J Gastroenterol Hepatol; 2018 Feb; 33(2):443-452. PubMed ID: 28573746
[TBL] [Abstract][Full Text] [Related]
58. Baseline gut microbial profiles are associated with the efficacy of
Hong G; Li Y; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
Scand J Gastroenterol; 2023 Apr; 58(4):339-348. PubMed ID: 36281578
[TBL] [Abstract][Full Text] [Related]
59. Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome.
Moser AM; Spindelboeck W; Halwachs B; Strohmaier H; Kump P; Gorkiewicz G; Högenauer C
Eur J Nutr; 2019 Oct; 58(7):2767-2778. PubMed ID: 30251020
[TBL] [Abstract][Full Text] [Related]
60. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification.
Lyra A; Rinttilä T; Nikkilä J; Krogius-Kurikka L; Kajander K; Malinen E; Mättö J; Mäkelä L; Palva A
World J Gastroenterol; 2009 Dec; 15(47):5936-45. PubMed ID: 20014457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
